Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,163 total articles
Erasca, Inc., a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its participation in the Jefferies Global Healthcare Conference. Management will present during a fireside chat and conduct investor meetings, with live and archived webcasts available through the company's website.
NewcelX Ltd., a clinical-stage regenerative medicine company, announced submission of a Pre-IND briefing package to the FDA supporting clinical trial initiation of NCEL-101 combined with tegoprubart for treating type 1 diabetes. The planned therapy aims at enabling durable graft survival without calcineurin inhibitors, potentially offering a functi…
HCW Biologics Inc. has exercised its option to regain exclusive ex vivo commercial rights to two advanced immunotherapeutic reagents, HCW9206 and HCW9201, from Wugen Inc. These reagents show promise for reducing CAR-T therapy manufacturing costs while improving efficacy by enriching long-lived T memory stem cells, potentially enabling more potent a…
VenHub Global, Inc. has opened its second, larger production and assembly facility in Las Vegas, significantly increasing its capacity to manufacture autonomous Smart Stores. This expansion supports faster delivery to meet growing commercial interest and builds on recent strategic agreements, including partnerships with LAX/Metro and Circa Resort &…
Fusion Fuel Green PLC released an investor update video and presentation detailing its strategic progress, financial targets for 2026 and 2027, and plans to acquire up to 100% of Royal Uranium. The company announced an Extraordinary General Meeting for June 8, 2026, to vote on the Royal Uranium acquisition, preferred shares conversion, and a propos…
Allot Ltd., a global provider of cybersecurity and network intelligence solutions, announced management will meet one-on-one with institutional investors during the William Blair Growth Stock Conference from June 2-4, 2026, in Chicago. The company offers comprehensive Security-as-a-Service and network platforms deployed worldwide across service pro…
Avis Budget Group announced its intention to issue $300 million in additional 8% senior notes due 2031 through a private offering. The proceeds, along with existing cash, will be used to redeem part of their 5.75% senior notes due 2027. The offering targets qualified institutional buyers under Rule 144A and is guaranteed by Avis Budget and some US …
FTI Consulting, Inc. announces the appointment of Damon Yousefy as Senior Managing Director in its Transactions practice, focusing on restructuring and bankruptcy tax. With extensive experience in distressed M&A and tax issues, Yousefy's addition is expected to bolster FTI's capabilities to support clients facing financial distress amid geopolitica…
Papa John's International, Inc. announced a global collaboration with Disney and Pixar to celebrate the release of Toy Story 5 in June 2026. The campaign includes themed personal pizzas, limited-edition collectibles, a special in-app game, and a custom-animated Pixar spot. Available in Canada and 42 international markets, this strategic partnership…
Abercrombie & Fitch Co. announced record first quarter net sales of $1.1 billion, a 2% increase from last year, marking the 14th consecutive quarter of growth. Growth was driven by the Americas and strong expansion in the Asia-Pacific region, while Europe, Middle East, and Africa (EMEA) experienced a 10% sales decline, notably impacted by Middle Ea…
Medline Inc. announced that its executive leadership team will participate in the William Blair and Goldman Sachs investor conferences in early June 2026, where they will present company insights and updates. Webcasts of these presentations will be available on Medline's Investor Relations website.
Abundia Global Impact Group, Inc. announces significant progress in its commercialization strategy for converting waste plastics and biomass into low-carbon fuels and chemicals. Key developments include securing Burns & McDonnell as lead engineer for front-end design, licensing Topsoe's HydroFlex® technology, acquiring project developer RPD Technol…
BridgeBio Pharma announced that the FDA has accepted its NDA for BBP-418 with Priority Review for treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a PDUFA date set for November 27, 2026. BBP-418 demonstrated strong efficacy in clinical trials, showing improvement in treated patients across key endpoints, and could become the…
Context Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in T cell engaging bispecific antibodies for solid tumors, announced its upcoming presentation at the Jefferies Global Healthcare Conference on June 3, 2026. The company also disclosed granting stock options to a new employee as an inducement to join the company, wit…
TG Therapeutics announced that its Phase 3 ENHANCE trial met its primary endpoint, demonstrating bioequivalent drug exposure between the approved two-infusion initiation regimen for BRIUMVI and a new single 600 mg infusion on Day 1 only, potentially streamlining treatment initiation for relapsing forms of multiple sclerosis (RMS). The simplified do…
Streamex Corp. (NASDAQ: STEX) partnered with Orca to launch a decentralized, 24/7 secondary liquidity infrastructure on the Solana blockchain for tokenized securities, starting with GLDY, a gold-backed, yield-bearing token. This infrastructure integrates regulatory compliance at the token level, enabling accredited investors to trade GLDY securely …
SOLOWIN HOLDINGS (Nasdaq: AXG) announced that its stablecoin subsidiary, AX Coin Bahrain, has signed a non-binding Memorandum of Understanding with The Benefit Company, Bahrain's national electronic financial transactions provider, to jointly explore stablecoin applications within Bahrain's regulated payments ecosystem. This collaboration aims to a…
Jupiter Neurosciences, Inc. announced the initiation of patient enrollment in its Phase 2a RESET clinical trial evaluating JOTROL™, an investigational oral drug candidate targeting Parkinson's Disease. The trial aims to explore JOTROL™'s potential to modify disease progression by addressing underlying neurodegenerative mechanisms. Parkinson's Disea…
Anterix, a leading provider of private wireless broadband spectrum for critical infrastructure, has appointed Kim Green-Kerr as Chief Revenue Officer. Her extensive experience in enterprise sales, particularly in utilities and critical infrastructure, positions her to accelerate customer engagement and deployment of Anterix's private wireless solut…
Palvella Therapeutics announced the issuance of a U.S. patent licensed from Yale University that strengthens intellectual property protection for its QTORIN™ pitavastatin program targeting porokeratosis, including disseminated superficial actinic porokeratosis (DSAP). This patent provides broad protection into 2043 for topical mevalonate pathway in…
Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, announced filing a provisional patent application for a Coaxial Dual-Propellant Grain Solid Rocket Motor (CDPG-SRM). The technology aims to extend range and endurance for small unmanned aerial vehicles used in defense, border security, and autonomous warfare, addressing key …
TransUnion has been named one of America’s Most Trustworthy Companies for 2026 by Newsweek, highlighting its commitment to integrity, responsible data stewardship, and innovation in credit reporting, fraud prevention, and consumer solutions. The accolade underscores TransUnion's focus on accuracy, fairness, transparency, and its strategy toward sus…
Maze Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference in June 2026. The company highlighted its clinical-stage biopharmaceutical pipeline focused on kidney and metabolic diseases, including two Phase 2 drug candidates.
Invivyd, Inc., a U.S.-based biopharmaceutical company specializing in antibody treatments for viral infectious diseases, announced it will participate in several investor events in June 2026, including the Jefferies Global Healthcare Conference, H.C. Wainwright Virtual Fireside Chat, and BTIG Infectious Disease Day. The company highlights its propr…
Atea Pharmaceuticals announced Phase 1 data indicating their fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus (HCV) treatment displays a low risk of drug-drug interactions, supporting its use alongside common medications such as omeprazole and rosuvastatin. Additionally, preclinical results for AT-587, a …
